



De

PATENT
ATTORNEY DOCKET NO.: 056291-5173

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:)
Ann-Margret LINDQVIST)
Application No.: 10/502,355) Group Art Unit: 1615
Filed: February 4, 2005) Examiner: Unassigned
FOR: USE OF BENZOTHIAZEPINES HAVING)
ACTIVITY AS INHIBITORS OF ILEAL)
BILE ACID TRANSPORT FOR REDUCING)
CHOLESTEROLEMIA)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop** ____
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: April 13, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(b)

Attached is a Form PTO-1449 listing the enclosed foreign patent documents.

Attached is a Form PTO-1449 listing the enclosed foreign patent documents.

Copies of any U.S. patent documents are not enclosed.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5173 and proceed to consider this IDS.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.


Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP. 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: April 13, 2005
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By:



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 056291-5173		Client Ref.			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Applicant: Ann Margaret Lindqvist					
				Appln. No.: 10/502,355					
				Filing Date: February 4, 2005					
				Examiner: Unassigned		Group Art Unit: 1615			
Date: April 13, 2005									
U.S. PATENT DOCUMENTS									
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)			
AR									
BR									
CR									
FOREIGN PATENT DOCUMENTS									
		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclosed	No
	DR	00/01687	01/2000	WO	Lee et al.				
	ER	00/38725	07/2000	WO	Keller et al.				
	AR	00/38726	07/2000	WO	Keller et al.				
	FR	00/38727	07/2000	WO	Keller et al.				
	BR	00/38728	07/2000	WO	Keller et al.				
	CR	00/38729	07/2000	WO	Keller et al.				
	DR	00/47568	08/2000	WO	Tollefson et al.				
	GR	00/61568	10/2000	WO	Frick et al.	X			X
**	HR	00/62810	10/2000	WO	Abrahamsson et al.				
	ER	01/60807 A1	08/2001	WO	Liu et al.				
	IR	01/66533 A	09/2001	WO	Starke et al.				
	FR	01/68096 A2	09/2001	WO	Keller et al.				
	GR	01/68637 A2	09/2001	WO	Babiak et al.				
	JR	Govers et al., Journa of Lipid Research, 35(5), 1994, pp. 741-748							
	KR	Higaki et al., Atherosclerosis, Thrombosis, and Vascular Biology, 18(8), Aug. 1998, pp. 1304-1311							
	LR	Ishibashi et al., Journal of Clinical Investigation, 92(2), Aug. 1, 1993, pp. 883-893, XP000574730, ISSN: 0021-9738							
	MR	Lewis et al., Journal of Lipid Research, (36), 1995, pp. 1098-1105							
	NR	Plump et al., Cell, (71), Oct. 16, 1992, pp. 343-353							
	OR	Schiller, Alimentary Pharmacology and Therapeutics, 15(6), 2001, pp. 749-763							
	PR	Sprong et al., J Nutrition (US), 2002, 132(6), pp. 1269-1274							
	QR	Van Tilburg et al., Gastroenterology, 98(1) 1989, pp. 25-32							
	RR	Welberg et al., Scandinavian J. Gastroenterology Suppl Norway, 188, 1991, pp. 52-59							
Examiner					Date Considered:				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.									

